The Extended Salford Lung Study ("Ex-SLS") Data Access Project

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03152669

Enrollment

1183

Registered

2017-05-15

Start date

2018-04-15

Completion date

2025-07-05

Last updated

2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

asthma, Chronic obstructive pulmonary disease, Salford Lung Study

Brief summary

The Salford Lung Study (SLS) subjects represent a group of COPD and asthma patients whose disease is extremely well-characterised over a short time period. Subjects in the SLS originally consented for information relevant to the study to be shared with the sponsor (GSK). These data were limited to three years prior to randomisation and the twelve-month interventional treatment period. Broadened access to patients' data would allow SLS subjects' entire disease journey to be researched, presenting a rare opportunity to improve scientific and clinical understanding of COPD/asthma disease risk, treatment and progression. This proposal seeks to collect additional subject-level data from SLS patients via their electronic medical records (encompassing past and future data for up to 10 years from the date of consent) and via a one-off patient questionnaire administered at the time of consent.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Subjects who were randomized to treatment in the original SLS studies * Subjects who are able to, and choose to, provide written consent for the additional information to be collected.

Exclusion criteria

* Subjects who were lost to follow-up/moved away, withdrew consent or died during or subsequent to the original SLS studies. * Subjects considered (at the discretion of the investigator) as too ill to participate or without the mental capacity to provide informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Retrospective EMR data	Up to 10 years	All historical data from consent until the beginning of patients' electronic health records, encompassing all routinely-available electronic demographic and health-related data back to a patients' earliest available electronic record.
Prospective EMR data	Up to 10 years	Prospective longitudinal data, encompassing collection of future routinely-recorded electronic demographic and health-related data for a period of ten years from this consent or until a patient is either lost to follow up or at the time of their death.
Risk factor questionnaire	Up to 10 years	Historical demographic, COPD/asthma risk factor information and clinical data not routinely available. Collected via paper questionnaire.

Countries

United Kingdom

Contacts

STUDY_DIRECTORGSK Clinical Trials

GlaxoSmithKline

Outcome results